FCSC - Fibrocell Science, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.50
-0.01 (-0.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.51
Open2.50
Bid2.41 x 1400
Ask2.60 x 1000
Day's Range2.41 - 2.55
52 Week Range2.21 - 19.70
Volume418,876
Avg. Volume821,884
Market Cap23.287M
Beta1.91
PE Ratio (TTM)N/A
EPS (TTM)-3.97
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.50
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Fibrocell Announces Closing of $4.0 Million Registered Direct Offering

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of its previously announced registered direct offering of 1,474,080 shares of its common stock which was priced at-the-market at a purchase price of $2.69 per share, for gross proceeds of approximately $3.9 million. Additionally, in a concurrent private placement, Fibrocell issued unregistered warrants to purchase a total of 958,152 shares of its common stock, representing 65% of the shares of common stock purchased in the registered direct offering. Each warrant was sold at a price of $0.125 per underlying warrant share, for gross proceeds of approximately $0.1 million.

  • Chester County gene therapy company expects $4M direct from direct stock offering
    American City Business Journals13 days ago

    Chester County gene therapy company expects $4M direct from direct stock offering

    The company is working on new treatments for skin and connective tissue disorders. It has one treatment under development to help 'butterfly children.'

  • GlobeNewswire13 days ago

    Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,474,080 shares of its common stock, at a purchase price per share of $2.69, for gross proceeds of approximately $3.9 million, in a registered direct offering priced at-the-market. Additionally, Fibrocell has also agreed to issue to the investors unregistered warrants to purchase up to 958,152 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.1 million. The warrants have an exercise price of $2.70 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...

  • Chester County gene therapy company completes $6M stock sale
    American City Business Journalslast month

    Chester County gene therapy company completes $6M stock sale

    The funds will be used by the Exton company to continue development of its new drug candidates for rare skin diseases.

  • Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?

    Fibrocell Science, Inc. (FCSC) has been struggling lately, but the selling pressure may be coming to an end soon

  • GlobeNewswirelast month

    Fibrocell Announces Closing of $6.0 Million Registered Direct Offering

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of its previously announced registered direct offering of 2,038,224 shares of its common stock which was priced at-the-market at a purchase price of $2.85 per share, for gross proceeds of approximately $5.8 million. Additionally, in a concurrent private placement, Fibrocell issued unregistered warrants to purchase a total of 1,528,668 shares of its common stock, representing 75% of the shares of common stock purchased in the registered direct offering. Fibrocell intends to use the net proceeds from this offering for the continued clinical and pre-clinical development of its product candidates, FCX-007 and FCX-013, and for other general corporate purposes.

  • GlobeNewswire2 months ago

    Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 2,038,224 shares of its common stock, at a purchase price per share of $2.85, for gross proceeds of approximately $5.8 million, in a registered direct offering priced at-the-market. Additionally, Fibrocell has also agreed to issue to the investors unregistered warrants to purchase up to 1,528,668 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.2 million. The warrants have an exercise price of $2.86 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • GlobeNewswire2 months ago

    Fibrocell Announces One-for-Five Reverse Stock Split

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it will effect a one-for-five reverse stock split of its common stock at 5:00 pm ET today.  Beginning with the opening of trading on May 25, 2018, the Company’s common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 315721407. Fibrocell’s stockholders approved an amendment authorizing the reverse stock split at its Annual Meeting of Stockholders on May 23, 2018.

  • ACCESSWIRE2 months ago

    Blog Exposure - Fibrocell Presented Update on Interim Results and Progress of its Phase-1/2 Clinical Trial of FCX-007 at International Investigative Dermatology Meeting

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Fibrocell Science, Inc. (NASDAQ: FCSC), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FCSC as the Company's latest news hit the wire. On May 21, 2018, the Company presented an update on the interim results and progress of its Phase-1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) at the 7th International Investigative Dermatology (IID) meeting held on May 19, 2018. Active-Investors.com is currently working on the research report for OptiNose, Inc. (NASDAQ: OPTN), which also belongs to the Healthcare sector as the Company Fibrocell Science.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Fibrocell Science Inc (NASDAQ: FCSC ) stock gained ...

  • GlobeNewswire2 months ago

    Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    –FCX-007 well-tolerated up to 52 weeks post-administration–. –Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of anchoring ...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 16) Abaxis Inc (NASDAQ: ABAX ) (announced a deal to be bought ...

  • GlobeNewswire2 months ago

    Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that an abstract will be presented in an oral session at the 7th International Investigative Dermatology (IID) meeting on May 19, 2018 at the Rosen Shingle Creek Resort in Orlando, Florida. The presentation will focus on the interim data from adult patients in the Phase 1 portion of the Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). On Monday, May 21, 2018 at 8:30 a.m. EDT, Fibrocell will host a conference call and webcast to discuss the interim results and progress of the Phase 1/2 clinical trial of FCX-007.

  • GlobeNewswire2 months ago

    Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the first quarter ended March 31, 2018 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “Our achievements in the first quarter of 2018 have set the stage for continued progress of Fibrocell’s gene therapy clinical programs that address rare conditions of the skin and connective tissue with high unmet needs,” said John Maslowski, President and Chief Executive Officer of Fibrocell.

  • GlobeNewswire2 months ago

    Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent operational highlights on Thursday, May 10, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.

  • What's in Store for Intrexon (XON) This Earnings Season?
    Zacks2 months ago

    What's in Store for Intrexon (XON) This Earnings Season?

    Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.

  • GlobeNewswire3 months ago

    Fibrocell Announces Review of Strategic Alternatives

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. Fibrocell has engaged Canaccord Genuity LLC as its strategic financial advisor to assist with this review process.

  • Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future?
    Simply Wall St.4 months ago

    Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future?

    Examining Fibrocell Science Inc’s (NASDAQ:FCSC) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations,Read More...

  • ACCESSWIRE4 months ago

    Fibrocell Science, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at 8:30 AM Eastern ...

  • Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
    Zacks4 months ago

    Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat

    Intrexon's (XON) loss in the fourth quarter of 2017 was narrower than expected.